Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics Cohort Using Multistate Modeling.
Journal
Arthritis care & research
ISSN: 2151-4658
Titre abrégé: Arthritis Care Res (Hoboken)
Pays: United States
ID NLM: 101518086
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
19
12
2022
received:
05
07
2022
accepted:
19
01
2023
pmc-release:
01
09
2024
medline:
31
8
2023
pubmed:
25
1
2023
entrez:
24
1
2023
Statut:
ppublish
Résumé
To estimate direct and indirect costs associated with neuropsychiatric (NP) events in the Systemic Lupus International Collaborating Clinics inception cohort. NP events were documented annually using American College of Rheumatology definitions for NP events and attributed to systemic lupus erythematosus (SLE) or non-SLE causes. Patients were stratified into 1 of 3 NP states (no, resolved, or new/ongoing NP event). Change in NP status was characterized by interstate transition rates using multistate modeling. Annual direct costs and indirect costs were based on health care use and impaired productivity over the preceding year. Annual costs associated with NP states and NP events were calculated by averaging all observations in each state and adjusted through random-effects regressions. Five- and 10-year costs for NP states were predicted by multiplying adjusted annual costs per state by expected state duration, forecasted using multistate modeling. A total of 1,697 patients (49% White race/ethnicity) were followed for a mean of 9.6 years. NP events (n = 1,971) occurred in 956 patients, 32% attributed to SLE. For SLE and non-SLE NP events, predicted annual, 5-, and 10-year direct costs and indirect costs were higher in new/ongoing versus no events. Direct costs were 1.5-fold higher and indirect costs 1.3-fold higher in new/ongoing versus no events. Indirect costs exceeded direct costs 3.0 to 5.2 fold. Among frequent SLE NP events, new/ongoing seizure disorder and cerebrovascular disease accounted for the largest increases in annual direct costs. For non-SLE NP events, new/ongoing polyneuropathy accounted for the largest increase in annual direct costs, and new/ongoing headache and mood disorder for the largest increases in indirect costs. Patients with new/ongoing SLE or non-SLE NP events incurred higher direct and indirect costs.
Identifiants
pubmed: 36691838
doi: 10.1002/acr.25090
pmc: PMC10363569
mid: NIHMS1868764
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1859-1870Subventions
Organisme : NCRR NIH HHS
ID : M01 RR000046
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001422
Pays : United States
Organisme : NIAMS NIH HHS
ID : P30 AR072579
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR043727
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR069572
Pays : United States
Organisme : NIAMS NIH HHS
ID : P60 AR064464
Pays : United States
Organisme : NIAMS NIH HHS
ID : P60 AR048098
Pays : United States
Organisme : NIAMS NIH HHS
ID : K24 AR002138
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : NCATS NIH HHS
ID : UL1 TR000150
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR025741
Pays : United States
Organisme : NIAMS NIH HHS
ID : P30 AR072579
Pays : United States
Informations de copyright
© 2023 American College of Rheumatology.
Références
Ann Rheum Dis. 2020 Mar;79(3):356-362
pubmed: 31915121
Stat Med. 2019 Jan 30;38(2):210-220
pubmed: 30207407
Arthritis Rheum. 1992 Jun;35(6):630-40
pubmed: 1599520
Rheumatology (Oxford). 2020 Dec 5;59(Suppl5):v52-v62
pubmed: 33280014
Semin Arthritis Rheum. 2011 Aug;41(1):1-11
pubmed: 20965549
J Med Econ. 2013;16(4):500-9
pubmed: 23363329
Arthritis Rheum. 1996 Mar;39(3):363-9
pubmed: 8607884
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032
Value Health. 2012 Jan;15(1):46-54
pubmed: 22264971
Arthritis Rheum. 2009 Sep 15;61(9):1159-67
pubmed: 19714597
Nat Rev Rheumatol. 2019 Mar;15(3):137-152
pubmed: 30659245
Rheumatology (Oxford). 2009 May;48(5):564-8
pubmed: 19269959
Arthritis Rheumatol. 2021 Dec;73(12):2293-2302
pubmed: 34042329
J Occup Environ Med. 2011 May;53(5):530-6
pubmed: 21508868
Arthritis Rheum. 1999 Apr;42(4):599-608
pubmed: 10211873
Lupus. 2022 Feb;31(2):202-211
pubmed: 35060407
J Autoimmun. 2016 Nov;74:41-72
pubmed: 27427403
Rheumatol Int. 2016 Nov;36(11):1507-1514
pubmed: 27534653
Pharmacoeconomics. 2013 Jan;31(1):49-61
pubmed: 23329592
Lupus. 2014;23(1):31-8
pubmed: 24243776
Arthritis Care Res (Hoboken). 2020 Dec;72(12):1800-1808
pubmed: 31609532
Arthritis Rheum. 2001 Oct;45(5):419-23
pubmed: 11642640
Ann Rheum Dis. 2010 Mar;69(3):529-35
pubmed: 19359262
Arthritis Care Res (Hoboken). 2018 Sep;70(9):1294-1302
pubmed: 29193883